通过分析14种癌症患者携带BRCA1/BRCA2致病性突变的频率,研究团队发现,男性乳腺癌患者携带BRCA2致病性突变的频率较高(18.9%);卵巢癌患者携带致病性突变的频率次之,其中4.86%存在BRCA1致病性突变,3.42%存在BRCA2致病性突变。 此外,还有6种癌症类型患者携带致病性突变的频率超过1%,其中2种携带BRCA1致病性突变,4种携带BRCA2...
通过分析14种癌症患者携带BRCA1/BRCA2致病性突变的频率,研究团队发现,男性乳腺癌患者携带BRCA2致病性突变的频率较高(18.9%);卵巢癌患者携带致病性突变的频率次之,其中4.86%存在BRCA1致病性突变,3.42%存在BRCA2致病性突变。 此外,还有6种癌症类型患者携带致病性突变的频率超过1%,其中2种携带BRCA1致病性突变,4种携带BRCA2...
通过分析14种癌症患者携带BRCA1/BRCA2致病性突变的频率,研究团队发现,男性乳腺癌患者携带BRCA2致病性突变的频率较高(18.9%);卵巢癌患者携带致病性突变的频率次之,其中4.86%存在BRCA1致病性突变,3.42%存在BRCA2致病性突变。 此外,还有6种癌症类型患者携带致病性突变的频率超过1%,其中2种携带BRCA1致病性突变,4种携带BRCA2...
通过分析14种癌症患者携带BRCA1/BRCA2致病性突变的频率,研究团队发现,男性乳腺癌患者携带BRCA2致病性突变的频率较高(18.9%);卵巢癌患者携带致病性突变的频率次之,其中4.86%存在BRCA1致病性突变,3.42%存在BRCA2致病性突变。 此外,还有6种癌症类型患者携带致病性突变的频率超过1%,其中2种携带BRCA1致病性突变,4种携带BRCA2...
Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 2012;14(3):409-14.D., McFarlandSusan, Miller-SamuelHank, SchmidtGloria J., Morris. (2015) Case Series: Five Individuals Diagnosed With Breast and Gastrointestinal Cancers: Are They “Related”?. ...
BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that es
BRCA1和BRCA2是乳腺癌易感基因(breast cancer susceptibility gene,BRCA),是重要的抑癌基因,其编码产物参与DNA损伤同源性重组修复(homologous recombination repair)。同源重组缺陷(homologous recombination deficiency,HRD)可以由BRCA1/2基因突变导致,使得基因组不稳定...
笔者认为,brca突变中brca2突变是主要预测因子之一,本文主要对brca1和brca2突变在前列腺癌中的相关研究进行讨论和分析。【关键词】 brca1 2、brca2 前列腺癌doi:10.14033/ki.cfmr.2019.30.081 a 1674-6805(2019)30-0-03abstract family history is one of the risk factors for prostate cancer, and breast ...
We found that carriers of BRCA2 mutations have a high risk of developing prostate cancer, particularly more aggressive prostate cancer, and that this risk varies by family history of prostate cancer and the location of the mutation within the gene....
Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening ...